PCOS vs. PMOS: What Does the Name Change Mean?

Medically Reviewed by Abinaya Muralidharan, M. Pharm - June 24, 2026

Introduction

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition formerly known as Polycystic Ovary Syndrome (PCOS), which impacts 1 in 8, or more than 170 million women worldwide. The 2012 National Institutes of Health (NIH) Evidence-Based Methodology Workshop on PCOS recommended the name change, noting that it could distract from the broader features of the condition. Following the 2012 NIH recommendation to reconsider the nomenclature, patient advocacy groups and professional societies increasingly emphasized that the term "polycystic ovaries" was misleading and contributed to substantial misunderstanding among affected individuals and healthcare providers.

Many women erroneously perceived that the presence of ovarian cysts was essential for diagnosis, despite polycystic ovarian morphology being neither necessary nor sufficient to establish the diagnosis. During this period, international collaborations expanded substantially, culminating in the development of global evidence-based initiatives such as the International PCOS Network and the 2018 International Evidence-Based Guideline for the Assessment and Management of PCOS. These joint efforts fostered broader stakeholder engagement, including patients, clinicians, and researchers, and intensified discussions regarding the need for a nomenclature that more accurately reflected the multisystem endocrine and metabolic nature of the disorder.

Between 2019 and 2025, extensive international stakeholder engagement shaped the evolving understanding and nomenclature of polycystic ovary syndrome. This collaborative process incorporated the perspectives of individuals with lived experience of the condition, researchers, endocrinologists, gynecologists, primary care physicians, allied health professionals, and representatives from major professional societies. The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS further emphasized that PCOS is a heterogeneous multisystem disorder with reproductive, metabolic, psychological, and long-term health implications extending beyond ovarian morphology and reproductive dysfunction. Building upon these recommendations, a formal global consensus initiative was undertaken to evaluate the appropriateness of the existing terminology. The consensus process employed rigorous methodological approaches, including international surveys, modified Delphi rounds, structured expert panel deliberations, and multistakeholder consultations across diverse geographical regions. This evidence-based and patient-inclusive approach ultimately reinforced the need for nomenclature that more accurately reflected the complex polyendocrine and metabolic pathophysiology of the disorder.

Professor Helena Teede, Director of Monash University’s Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health, spearheaded the name change process after decades of researching the condition and witnessing its impact on patients firsthand. In May 2026, a worldwide interdisciplinary consortium formally proposed renaming Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The advice was disseminated in The Lancet and shared at the European Congress of Endocrinology (ECE) 2026, representing a pivotal advancement in women's endocrine health in decades.

What Does PMOS Mean?

PMOS is a complex, multigenic disorder extending beyond ovarian morphology to encompass endocrine and metabolic dysfunction.

Understanding the Polyendocrine Nature of PMOS

• Ovulatory dysfunction and hyperandrogenism are both caused by dysregulation of ovarian steroidogenesis, which is a contributing factor.
• One of the most important aspects of the pathophysiology of the disease is the presence of impaired insulin signaling and compensatory hyperinsulinemia.
• There is a correlation between the presence of an excess of adrenal androgen and the clinical and biochemical heterogeneity of the disease.
• The expression of disease and the dangers to one's health over the long run are both influenced by altered interactions between endocrine and metabolic pathways.

Why "Metabolic" Was Added

• Insulin resistance is a characteristic that manifests itself in a significant number of people, even those who have a normal body weight.
• Women who suffer from premenstrual syndrome are at a greater risk of developing prediabetes and impaired glucose tolerance.
• There is a substantially increased lifetime risk of developing type 2 diabetes.
• MASLD (metabolic dysfunction–associated steatotic liver disease) is more common among individuals with metabolic dysfunction.
• The presence of adverse cardiometabolic profiles is a contributing factor to the increasing burden of cardiovascular risk factors.

The Ovarian Factor

Ovarian dysfunction – persistent anovulation, monthly abnormalities, infertility, and hyperandrogenic symptoms – continues to be a fundamental clinical hallmark of the disease.

How Could the New Name Improve Diagnosis and Awareness?

PMOS replaces PCOS to reflect the disorder's multisystem pathophysiology. Renaming may resolve various obstacles to swift diagnosis and comprehensive care, while evidence is still developing.

Why are diagnosis and care often delayed?

• Inadequate awareness among patients and providers

The limited understanding of the disorder's extensive clinical range of symptoms leads to delayed diagnosis and inconsistent management. The 2023 International Guideline recognized enduring discrepancies between evidence and practice, notwithstanding progress in diagnostic criteria.

• Absence of fertility concerns

Several PMOS patients demonstrate metabolic, dermatologic, or psychiatric symptoms instead of infertility, leading to overlooked diagnostic chances in the absence of reproductive issues.

• Lack of awareness of the interconnectedness of symptoms

Instead of being treated as symptoms of a single underlying illness, menstrual irregularities, acne, hirsutism, weight gain, insulin resistance, and mood disorders are frequently treated as separate complaints.

• The presumption that the presence of ovarian cysts is a requisite

Although polycystic ovarian morphology is neither essential nor sufficient for diagnosing the disorder, the phrase "polycystic ovaries" has caused significant misunderstanding because many patients and medical professionals mistakenly believe that ovarian cysts are necessary for diagnosis.

Why the name change matters for patient care

Polycystic ovary syndrome has traditionally been viewed as a gynecological or fertility ailment due to its focus on ovarian shape and reproductive symptoms. However, extensive data show that the syndrome is a complicated multisystem disorder, including endocrine, metabolic, reproductive, and psychological problems. Polyendocrine Metabolic Ovarian Syndrome was coined to better reflect this pathophysiology and broaden clinical attention beyond fertility and ovarian disorders.

The new terminology emphasizes the need for a comprehensive, patient-centered approach to care that addresses all health risks, including insulin resistance, type 2 diabetes, metabolic dysfunction–associated steatotic liver disease (MASLD), cardiovascular risk factors, sleep disturbances, and mental health disorders. PMOS may encourage multidisciplinary management by gynecologists, endocrinologists, primary care physicians, dietitians, psychologists, and other allied health professionals to assess, treat, and follow up the condition's interconnected endocrine and metabolic components.

Will the Diagnostic Criteria Change?

What stays the same

The diagnostic criteria for PCOS have not changed since its rebranding to PMOS. The 2023 International Evidence-Based Guideline still requires at least two of the following after exclusion of related disorders: ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. Nomenclature change is a conceptual shift, not an immediate diagnostic practice change.

What may evolve in the future

It is expected that there would be greater emphasis on the following:

• Metabolic screening

The high incidence of metabolic disorders may encourage routine glycemic and metabolic health assessments.

• Insulin resistance assessment

Future treatment pathways may include systematic assessment of insulin-related dysfunction, especially in high-risk individuals, owing to the key role of insulin resistance in disease pathogenesis.

• Cardiovascular risk factors

Increased examination of cardiovascular risk variables such as blood pressure, dyslipidemia, obesity, and others may become part of normal care.

• Mental health evaluation

Anxiety, depression, diminished quality of life, and body image issues are frequent but underrecognized; systematic psychological assessment may play a larger role in complete management.

More comprehensive screening may include

• Blood glucose testing

Periodic fasting plasma glucose, HbA1c, or oral glucose tolerance tests can detect decreased glucose tolerance and type 2 diabetes early.

• Cholesterol monitoring

Lipid profile screening is advised for dyslipidemia, which often accompanies the syndrome and increases cardiometabolic risk.

• Liver health assessments

Evaluation for metabolic dysfunction-associated steatotic liver disease (MASLD) may be recommended for persons with metabolic risk factors due to its higher prevalence in this population.

• Sleep health evaluations

Screening for obstructive sleep apnea and sleep disruptions may be recommended, especially for people with obesity or suggestive symptoms, as they are linked to poor metabolic outcomes.

PMOS does not redefine who receives the diagnosis, but it broadens the therapeutic perspective to evaluate and manage the disorder's endocrine, metabolic, cardiovascular, hepatic, psychological, and sleep-related effects.

What Does This Mean for People Already Diagnosed?

Your diagnosis is still valid

Previous diagnoses are not invalidated by the transition from PCOS to PMOS. PMOS is a renamed disease to better reflect its complex endocrine and metabolic features. No urgent adjustments are needed to diagnosis or therapy for PCOS patients who match the diagnostic criteria.

The clinical picture has not changed; however, the new language allows for a better grasp of the clinical presentation. Besides reproductive aspects such as monthly abnormalities, hyperandrogenism, and infertility, more emphasis may be given to the concomitant metabolic, cardiovascular, hepatic, sleep, and psychological comorbidities. This could mean more complete evaluation and follow-up care for individuals to improve general health outcomes, rather than focusing only on fertility-related issues.

Will doctors still use the term PCOS?

Yes, during the changeover period, many healthcare professionals are likely to use both PCOS and PMOS interchangeably to help ensure continuity of care and reduce confusion among patients and providers. Medical records, electronic health records, insurance forms, and research publications may still use PCOS until clinical guidelines, classification systems, and coding systems are formally revised. Thus, the adoption of PMOS is expected to be gradual through evolving professional recommendations and educational initiatives.

Will Treatments Change?

What will likely stay the same

The move from PCOS to PMOS is unlikely to lead to any immediate changes in conventional treatment techniques. Management will continue to rest on current evidence-based therapies.

• Lifestyle interventions

Healthy food patterns, regular physical exercise, behavioral techniques, and sleep optimization are still first-line therapy for optimizing reproductive and metabolic outcomes.

• Weight management strategies

Evidence-based weight management measures are still suggested for those living with overweight or obesity to improve ovulatory function, metabolic parameters, and quality of life. 

• Fertility treatments

Standard treatments such as ovulation induction drugs (eg, letrozole), assisted reproductive technologies if indicated, and fertility counseling remain key components of therapy for those attempting conception. 

• Hormonal therapies

Combined oral contraceptives and other hormonal agents will continue to be utilized for the treatment of monthly irregularities, hyperandrogenic symptoms, and endometrial protection.

What may receive greater attention

The treatment principles remain substantially the same, but the PMOS name may encourage a more general, preventive approach to long-term health.

• Metabolic health optimization

A potential increased focus on optimizing overall metabolic health by early identification and therapy of dysglycemia, obesity, and metabolic dysfunction.

• Insulin resistance management

Accepting insulin resistance as a core feature of the condition might prompt more aggressive use of lifestyle modifications and insulin-sensitizing medications such as metformin in appropriate patients.

• Cardiovascular disease prevention

Routine treatment should better incorporate improved surveillance and control of cardiovascular risk factors such as hypertension, dyslipidemia, and central adiposity.

• Long-term risk reduction

More emphasis may be placed on prevention of future issues through continued surveillance, patient education, and lifelong follow-up for metabolic, psychosocial, hepatic, and reproductive health.

In summary, PMOS does not deliver novel medicines, but rather shifts the goals of care from largely symptom-based and fertility-centered management to overall lifelong optimization of reproductive, endocrine, metabolic, and cardiovascular health.

PMOS vs. PCOS: A Side-by-Side Comparison

Emerging Areas of Interest in PMOS Research

As the concept of Polyendocrine Metabolic Ovarian Syndrome emphasizes the multisystem nature of the disorder, current research is increasingly focused on identifying strategies that address its metabolic heterogeneity, underlying biology, and long-term health consequences.

Metabolic Health Management

• Insulin-sensitizing therapies

Given the central role of insulin resistance in many individuals with PMOS, ongoing research continues to evaluate the optimal use of insulin-sensitizing agents, particularly metformin, to improve metabolic and reproductive outcomes.

• GLP-1 receptor agonists and obesity medicine approaches

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including agents used in obesity medicine, have emerged as promising therapies for weight reduction and improvement of insulin sensitivity, with growing evidence supporting their potential role in selected patients with PMOS.

• Metabolic therapies

Novel therapeutic approaches targeting dysglycemia, adipose tissue dysfunction, and metabolic abnormalities are being investigated to complement traditional symptom-based management.

• Cardiovascular prevention

Increasing attention is being directed toward early identification and modification of cardiovascular risk factors, including hypertension, dyslipidemia, obesity, and endothelial dysfunction, to reduce long-term morbidity.

Personalized and Precision Medicine

The marked heterogeneity of PMOS has stimulated interest in precision medicine approaches that tailor prevention and treatment strategies according to individual phenotypes, metabolic profiles, genetic susceptibility, and patient priorities rather than adopting a uniform treatment model.

Understanding the Underlying Biology of PMOS

• Gut microbiome research

Alterations in gut microbial composition and diversity have been implicated in insulin resistance, hyperandrogenism, and chronic low-grade inflammation, suggesting a potential role for the gut microbiota in disease pathogenesis and future therapeutic interventions.

• Chronic inflammation

Evidence indicates that persistent low-grade inflammation may contribute to metabolic dysfunction, ovarian dysfunction, and cardiovascular risk, highlighting inflammatory pathways as potential therapeutic targets.

Mental Health Outcomes

Research increasingly recognizes the substantial burden of anxiety, depression, body image concerns, and reduced quality of life among individuals with PMOS, underscoring the importance of integrating psychological health into both clinical care and future research agendas.

Overall, these emerging areas reflect a transition from a predominantly reproductive focus toward a broader understanding of PMOS as a complex endocrine–metabolic disorder requiring individualized, preventive, and multidisciplinary approaches.

5 Myths the New PMOS Name Finally Corrects

• Everyone with PCOS has ovarian cysts 

Reality: Polycystic ovarian morphology is not necessary for diagnosis. In the absence of ovarian cysts, the diagnosis can be made according to the Rotterdam criteria if there are other characteristics such as ovulatory failure and hyperandrogenism. On the other hand, many people with polycystic ovarian morphology do not have the syndrome. One of the main reasons for the shift towards PMOS terminology was the confusion generated by the word “polycystic”.

• The condition only affects fertility (pregnancy is impossible with PCOS)

Reality: Pregnancy is feasible, although PMOS often impacts ovulation and fertility. Many people conceive naturally, while others may need ovulation induction or assisted reproductive technology. Crucially, the disease also has implications for metabolic, endocrine, and psychological health throughout the life course, and should not be considered in isolation from fertility.

• If you can get pregnant, you don't have PCOS

Reality: You can still get pregnant after diagnosis. Ovulation in PMOS may be sporadic, and some women may have substantially intact reproductive function despite satisfying the diagnostic criteria. A successful pregnancy does not therefore exclude the presence of the disease.

• PCOS is just a gynecological disorder

Reality: PMOS is becoming recognized as a multisystem illness affecting the reproductive, endocrine, metabolic, cardiovascular, and psychological domains. In addition to the symptoms of menstruation and androgens, some may experience sleep problems, anxiety, sadness, low quality of life, insulin resistance, dyslipidemia, and decreased glucose tolerance.

• Weight gain is the only metabolic concern

Fact: Excess weight may aggravate symptoms and metabolic risk, although metabolic dysfunction happens in people with a normal body mass index. Irrespective of body weight, insulin resistance, prediabetes, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and unfavorable cardiovascular risk profiles may occur. Therefore, a complete metabolic work-up is warranted in all affected people.

Collectively, these myths emphasize the potential of the name PMOS to increase public knowledge by emphasizing that the illness is not limited to ovarian cysts, infertility, and body weight but involves wider endocrine and metabolic health.

To search for the best Endocrinology healthcare providers in Azerbaijan, Germany, India, Malaysia, Spain, Thailand, Turkey, UAE, UK and the USA, please use the Mya Care search engine.

 

References:

Show All ▼

 

Disclaimer